Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
The FDA accepted Apnimed's NDA for AD109 (Oxnimbi) with a PDUFA target action date of February 28, 2027, marking a key regulatory milestone for the company's lead asset. The company completed an upsized IPO raising $220.8 million, strengthening its financial position to support commercial readiness activities and a potential U.S. launch.
Key figures
- Eps
- 3.91
- Net Income
- 125935000
- Deal Value Usd
- 220800000
- Offering Price
- 16
- Shares Offered
- 13800000
- Cash And Cash Equivalents
- 172804000
- Drug name
- AD109 (Oxnimbi)
- Pdufa date
- February 28, 2027
- Ga expenses
- 12674000
- Rd expenses
- 9900000
- Phase of trial
- NDA review
- Interest income
- 970000
- Revenue related party
- 12080000
- Gain on deposit liability
- 57120000
- Gain on equity method investment
- 85380000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.